Company news

Precigen, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Precigen Achieves Significant Clinical Progress for UltraCAR-T® and AdenoVerse™ Therapies

November 3, 2021

Precigen to Host R&D Update Virtual Event on November 4th to Share Clinical Developments

October 26, 2021

Precigen Announces Clearance of IND to Initiate Phase 1/1b Study for PRGN-3007 UltraCAR-T® in Advanced ROR1+ Hematological and Solid Tumors

October 25, 2021

Precigen Appoints Harry Thomasian Jr. as Chief Financial Officer

October 11, 2021

Precigen ActoBio Announces Additional Positive Interim Data from Phase 1b/2a Study of AG019 ActoBiotics™, A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes

September 30, 2021

Precigen to Present at the 2021 Wells Fargo Virtual Healthcare Conference and the H.C. Wainwright 23rd Annual Global Investment Conference

August 31, 2021

Precigen Reports Second Quarter and First Half 2021 Financial Results

August 8, 2021

Precigen to Announce Second Quarter and First Half 2021 Financial Results on August 9th

August 1, 2021

Precigen to Present at the JMP Securities Life Sciences Conference

June 9, 2021

Precigen ActoBio Announces Positive Topline Results from Phase 1b/2a Study of AG019 ActoBiotics™, A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes

June 9, 2021

Precigen Reports First Quarter 2021 Financial Results

May 9, 2021

Precigen Announces Departure of Chief Financial Officer

March 29, 2021

Precigen Announces First Patient Dosed for PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP)

March 22, 2021

Precigen Receives FDA Orphan Drug Designation for PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP)

March 17, 2021

Precigen Reports Fourth Quarter and Full Year 2020 Financial Results

February 28, 2021

Precigen to Announce Fourth Quarter and Full Year 2020 Financial Results on March 1st

February 21, 2021

Precigen to Participate in Guggenheim Healthcare Talks Oncology Day

February 3, 2021

Precigen Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares

January 25, 2021

Precigen Announces Pricing of $112.5 Million Public Offering of Common Stock

January 21, 2021

Precigen Announces Proposed Public Offering of Common Stock

January 20, 2021

Precigen Provides Pipeline Updates at the 39th Annual J.P. Morgan Healthcare Conference

January 12, 2021

Precigen to Present at the 39th Annual J.P. Morgan Healthcare Conference

January 5, 2021

Precigen Announces Clearance of IND to Initiate Phase I Study of PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP)

January 4, 2021

Precigen Provides Latest Clinical Developments at Virtual R&D Update Event

December 14, 2020

Precigen to Host R&D Update Virtual Event on December 15th to Share Latest Clinical Developments

December 7, 2020

Precigen Presents New Data Supporting the Safety, Clinical Activity, Expansion and Persistence of PRGN-3006 UltraCAR-T® at the 62nd ASH Annual Meeting and Exposition

December 6, 2020

Precigen Announces Dosing of First Patients with UltraCAR-T® Cells Manufactured Using Proprietary UltraPorator™ System in Ongoing PRGN-3005 and PRGN-3006 Phase 1 Clinical Trials

November 15, 2020

Precigen Reports Third Quarter 2020 and Year-to-Date Financial Results

November 8, 2020

Precigen to Announce Third Quarter 2020 Financial Results on November 9th: Will host Pipeline and Data Update Call in Early December

November 1, 2020

Precigen Strengthens Focus on Strategic Partnerships and Names Gaurav Vij Head of Business Development

October 19, 2020

Precigen's UltraPorator™ Receives FDA Clearance for Manufacturing UltraCAR-T® Cells in Clinical Trials

October 14, 2020

Precigen Announces Merck KGaA, Darmstadt, Germany Increases Ownership Position Through Exercise of Convertible Note

October 8, 2020

Precigen to Present at H.C. Wainwright 22nd Annual Global Investment Conference

September 7, 2020

Precigen Announces First Patient Dosed in Phase I/II Study of First-in-Class PRGN-2009 AdenoVerse™ Immunotherapy to Treat HPV-associated Cancers

August 16, 2020

Precigen Reports Second Quarter and First Half 2020 Financial Results

August 9, 2020

Precigen ActoBio Announces Positive Topline Results from Phase 1b Study of AG019 ActoBiotics™, A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes

August 9, 2020

Precigen Triple-Gene Provides Six-month Follow-up Data from Phase I Study of INXN-4001, a Multigenic Investigational Therapeutic Candidate for Heart Failure

August 5, 2020

Precigen to Announce Second Quarter and First Half 2020 Financial Results on August 10th

August 2, 2020

Preclinical Data for PRGN-3005 UltraCAR-T® Demonstrate Superior Expansion and Persistence of UltraCAR-T Compared to Traditional CAR-T

June 21, 2020

Precigen to Participate in Upcoming JMP Securities Hematology and Oncology Forum

June 10, 2020

Notice: Precigen Announces Date and Location Change for its 2020 Annual Meeting of Shareholders

June 3, 2020

Precigen to Present Preclinical Data for PRGN-3005 UltraCAR-T™ at the AACR Virtual Annual Meeting II in June 2020

May 14, 2020

Precigen Reports First Quarter 2020 Financial Results

May 5, 2020

Precigen to Announce First Quarter 2020 Financial Results on May 6th

April 28, 2020

Precigen Announces Clearance of IND to Initiate Phase I/II Study for First-in-Class PRGN-2009 AdenoVerse™ Immunotherapy to Treat HPV-positive (HPV+) Solid Tumors

April 19, 2020

Precigen Reports Fourth Quarter and Year End 2019 Financial Results

March 1, 2020

Precigen to Announce Fourth Quarter and Full Year 2019 Financial Results on March 2nd

February 23, 2020

Precigen Receives FDA Orphan Drug Designation for PRGN-3006 UltraCAR-T(TM) in Patients with Acute Myeloid Leukemia (AML)

January 5, 2020

Intrexon To Achieve $175M Cash Goal, Appoints Helen Sabzevari, PhD, As New President And CEO And Will Change Name To Precigen To Reflect Healthcare Focus

January 1, 2020

Triple-Gene Presented Preliminary Phase 1 Trial Data of Investigational Multigenic Therapeutic Candidate INXN-4001 for Treatment of Heart Failure at American Heart Association Annual Meeting

November 17, 2019

← Newer news releases · Older news releases →

Calls

The 5 newest of 14 calls. Every call is listed under its year.

Decks

The 5 newest of 34 decks. Every deck is listed under its year.